AZD6244 (ARRY-142886) Solid Oral Dosage Formulation in Patients With Advanced Solid Malignancies
AZD6244 (ARRY-142886) Solid Oral Dosage Formulation in Patients With Advanced Solid Malignancies
The primary purpose of the study is to assess the safety, tolerability and pharmacokinetics
 of a capsule of AZD6244 in patients with advanced solid malignancies.
Inclusion Criteria:

 -  cancer which is refractory to standard therapies

 -  WHO performance status 0-2

 -  evidence of post-menopausal status or negative pregnancy test

 Exclusion Criteria:

 -  Radiotherapy/chemotherapy within 21 days prior to entry

 -  brain metastases/spinal cord compression unless stable off steroids/anticonvulsants

 -  evidence of severe/uncontrolled systemic disease

 -  participated in an investigational drug study within 30 days